DIESSE is an Italian developer of innovative In Vitro Diagnostic systems for the diagnosis of infectious and autoimmune diseases, and hematology systems for the assessment of inflammation. A mainstay of DIESSE’s strategy is the in-house production of most of the basic biologic components of the diagnostic kits (polyclonal and monoclonal antibodies, native and recombinant antigens), along with the capacity to design instruments and dedicated plastic devices in order to develop close automated systems.

DIESSE was founded in Siena (Italy) in 1980 by a group of Tuscan research scientists. The founders, including Mr. Carlo Arezzini, Mr. Francesco Cocola, Mr. Franco Meiattini, Mr. Antonio Ricci, together with their long-time partner Mr. Sergio Benocci, instilled a strong culture of innovation and quality, which helped to drive the development of DIESSE’s strong brand across key markets.

www.diesse.it/

INVESTMENT DATE 
2019

SECTOR
Diagnostics

TRANSACTION TYPE 
Carve-Out

GROWTH THEME
Innovation / Internationalisation

LOCATION
Italy